Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dronabinol + megestrol acetate
- Development stage
- Phase 1
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of dronabinol (a synthetic cannabinoid) and megestrol acetate (a synthetic progestin). This combination has been studied for the treatment of cancer-associated anorexia and cachexia, though clinical trials have shown that the combination does not provide significant additional benefits over megestrol acetate alone. Megestrol acetate works by reducing inflammation and potentially stimulating neuropeptide Y, while dronabinol acts on cannabinoid receptors to stimulate appetite.
02
Targets
CNR1 (Cannabinoid receptor 1)PR (Progesterone receptor)
Beyond the preview
Go deeper on dronabinol + megestrol acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dronabinol + megestrol acetate.